182 related articles for article (PubMed ID: 35932175)
61. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
Chang HP; Cheung YK; Shah DK
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807057
[TBL] [Abstract][Full Text] [Related]
62. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
63. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
64. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
65. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
66. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
Front Immunol; 2018; 9():1799. PubMed ID: 30123222
[TBL] [Abstract][Full Text] [Related]
67. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
68. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
69. Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.
Lu D; Gibiansky L; Agarwal P; Dere RC; Li C; Chu YW; Hirata J; Joshi A; Jin JY; Girish S
CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):665-673. PubMed ID: 27863168
[TBL] [Abstract][Full Text] [Related]
70. Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.
Theunissen JW; Cai AG; Bhatti MM; Cooper AB; Avery AD; Dorfman R; Guelman S; Levashova Z; Migone TS
Mol Cancer Ther; 2018 Nov; 17(11):2412-2426. PubMed ID: 30126944
[TBL] [Abstract][Full Text] [Related]
71. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
72. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
73. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
[TBL] [Abstract][Full Text] [Related]
74. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
Bordeau BM; Nguyen TD; Polli JR; Chen P; Balthasar JP
Mol Cancer Ther; 2023 Apr; 22(4):459-470. PubMed ID: 36723609
[TBL] [Abstract][Full Text] [Related]
75. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
[TBL] [Abstract][Full Text] [Related]
76. Development and validation of bioanalytical methods to support clinical study of disitamab vedotin.
Wu B; Li Q; Wang L; Chen F; Jiang J
Bioanalysis; 2024; 16(9):385-400. PubMed ID: 38530234
[TBL] [Abstract][Full Text] [Related]
77. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
[TBL] [Abstract][Full Text] [Related]
78. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
79. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Naumovski L; Junutula JR
Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
[TBL] [Abstract][Full Text] [Related]
80. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]